CSLCSLLY +1.84%73 Peter Lynch Fair Value is $12.98 as of Jul. 01, 2026, which is 401% above its 10-year median of 2.59. GuruFocus rates CSLLY with a GF Score™ of 73/100 and a GF Value™ of $51.03 (Significantly Undervalued). The stock has 7 warning signs investors should review. Among 68 Biotechnology companies, CSL ranks better than 54.41% on this metric.
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year. Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years. If 5-Year Growth Rate is greater than 25% a year, we use 25. If 5-Year Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Here, as of today, CSL's PEG is 1. CSL's 5-Year TTM EBITDA Growth Rate is 8.41.
CSL's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $1.54. Therefore, the Peter Lynch Fair Value for today is $12.98.
As of today (2026-07-01), CSL's share price is $20.43. CSL's Peter Lynch fair value is $12.98. Therefore, CSL's Price to Peter Lynch Fair Value Ratio for today is 1.57.
The historical rank and industry rank for CSL's Peter Lynch Fair Value or its related term are showing as below:
CSLLY'
s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.11 Med: 2.59 Max: 5.46
Current: 1.15
During the past 13 years, the highest Price to Peter Lynch Fair Value Ratio of CSL was 5.46. The lowest was 1.11. And the median was 2.59.
CSLLY's Price-to-Peter-Lynch-Fair-Value is ranked better than 54.41% of 68
companies
in the Biotechnology industry
Industry Median: 1.21
vs CSLLY: 1.15
Note: Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart.
CSL (OTCPK:CSLLY) Peter Lynch Fair Value Explanation
Peter Lynch Fair Value applies to growing companies. The ideal range for the growth rate is between 10 - 20% a year.
Peter Lynch thinks that the fair P/E value for a growth company equals its growth rate, that is PEG = 1. The earnings here is trailing twelve month (TTM) earnings. For non-bank companies, the growth rate we use is the average growth rate for EBITDA per share over the past 5 years. For Banks, the growth rate we use is the average growth rate for Book Value per share over the past 5 years.
Please don't confuse Peter Lynch Fair Value with the value reached in Peter Lynch Chart. In Peter Lynch chart, a fixed P/E ratio of 15 is used to draw the Earnings Line. Therefore the value reached has a P/E ratio of 15. But in Peter Lynch Fair Value calculation, P/E equals to the growth rate of EBITDA per share over the past 5 years, which is 8.41 instead of 15 in this case.
CSL's Price to Peter Lynch Fair Value Ratio for today is calculated as
Price to Peter Lynch Fair Value
=
Share Price
/
Peter Lynch Fair Value
=
20.43
/
12.98
=
1.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSL Peter Lynch Fair Value Related Terms
CSL Peter Lynch Fair Value Historical Data
* Premium members only.
The historical data trend for CSL's Peter Lynch Fair Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSLLY vs VRTX, REGN, ALNY: Peter Lynch Fair Value Comparison
For the Biotechnology subindustry, CSL's Price-to-Peter-Lynch-Fair-Value, along with its competitors' market caps and Price-to-Peter-Lynch-Fair-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CSL Price-to-Peter-Lynch-Fair-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CSL's Price-to-Peter-Lynch-Fair-Value distribution charts can be found below:
* The bar in red indicates where CSL's Price-to-Peter-Lynch-Fair-Value falls into.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CSL's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 was $1.54.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Please be aware that the 5-Year TTM EBITDA Growth Rate is calculated based on TTM data over the last 5 years. For quarterly reported companies, the TTM data adds up the quarterly data reported by the company within the most recent 12 months. For companies that report semi-annually, annually, or do not have enough quarterly data, GuruFocus uses the annual data as the TTM data.
If 5-Year Earnings Growth Rate is greater than 25% a year, we use 25.
If 5-Year Earnings Growth Rate is smaller than 5% a year, we do not calculate Peter Lynch Fair Value.
Please note that we use the 5-year average growth rate of EBITDA per share as the growth rate for non-bank companies, as EBITDA growth is subject to less manipulations than net earnings per share. For banks, we use the 5-year average growth rate of Book Value per share as the growth rate. The reason is that EBITDA is not applicable to Banks and Book value is a relative important measurement for Banks. In the calculation, PEG=1 because Peter Lynch thinks that the fair P/E ratio of the growth stock is equal to its earnings growth rate.
What does a Peter Lynch Fair Value of $12.98 mean?
CSL (CSLLY) has a Peter Lynch Fair Value of $12.98 as of Jul. 01, 2026. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CSL and its competitors. This is 401% above median its historical median of 2.59. Over the past decade, CSL's Peter Lynch Fair Value has ranged from 1.11 to 5.46. According to the industry distribution chart, CSL ranks #31 out of 68 companies in the Biotechnology industry, placing it in the top 45.6%.
Is CSL's Peter Lynch Fair Value too high?
CSL's current Peter Lynch Fair Value of $12.98 is 401% above median its 10-year median of 2.59. Over the past 10 years, this metric has ranged from a low of 1.11 to a high of 5.46. The Biotechnology industry median Peter Lynch Fair Value is 1.21. CSL's value of $12.98 is 972.7% above this industry median. Based on the distribution chart, CSL ranks #31 out of 68 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CSL has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CSL's Peter Lynch Fair Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CSL ranks #31 out of 68 companies for Peter Lynch Fair Value. This puts CSL in the upper half of its industry. The industry median Peter Lynch Fair Value is 1.21. CSL's value of $12.98 is 972.7% above this benchmark. Historically, CSL's own Peter Lynch Fair Value has ranged from 1.11 to 5.46 over the past decade. While the company's 10-year median is 2.59 vs. the industry median of 1.21, CSL has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Peter Lynch Fair Value for a Biotechnology company?
The median Peter Lynch Fair Value among Biotechnology companies is 1.21, based on 68 companies in the industry. Companies in the top quartile (top 25%) have a Peter Lynch Fair Value significantly above this median, while those in the bottom quartile fall well below. However, Peter Lynch Fair Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CSL's current Peter Lynch Fair Value of $12.98 is 972.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Peter Lynch Fair Value mean?
A high Peter Lynch Fair Value can signal that a stock is expensive relative to its fundamentals. Peter Lynch Fair Value is the stock value based on a company's current earnings and five-year earnings growth, assuming a PEG of one. View historical data on CSL and its competitors. For the Biotechnology industry, the median Peter Lynch Fair Value is 1.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CSL's current Peter Lynch Fair Value is $12.98, which is 401% above median its own 10-year median of 2.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CSL stock overvalued right now?
Based on GuruFocus' analysis, CSL (CSLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $51.03, compared to a current price of $20.43 — trading 60% below its estimated fair value. The current Peter Lynch Fair Value is $12.98, which is 401% above median its 10-year median of 2.59 and 972.7% above the Biotechnology industry median of 1.21. CSL's overall GF Score™ is 73/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Peter Lynch Fair Value calculated?
Peter Lynch Fair Value is calculated from a company's financial statements. For CSL (CSLLY), the current Peter Lynch Fair Value is $12.98 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CSL (CSLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CSL stock appears to be undervalued.
The current stock price of $20.43 is trading 60% below its estimated GF Value™ of $51.03.
GuruFocus considers CSL to be Significantly Undervalued.
Key valuation signals for CSLLY:
Peter Lynch Fair Value: $12.98 (401% above median its 10-year median of 2.59)
GF Value™: $51.03 vs. price of $20.43 (60% below fair value)
Industry Position: 972.7% above the Biotechnology median (#31 of 68)
No single metric tells the full story. See the CSLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world's second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.
73GF Score
Get the complete analysis for CSLLY
Peter Lynch Fair Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSLLY has been successfully added to your 
